Document resource
Objective The analysis compared discontinuation and adverse events (AEs) over 12-months of open-label as needed use for rimegepant and triptan-treated subjects using a matching-adjusted indirect comparison (MAIC).Methods Proportions of categorical fields and means of continuous fields were matched. Individual patient data from rimegepant trial NCT03266588 were weighted to match baseline covariates in a zolmitriptan long-term study population. Outcomes included discontinuation over 12 months (overall and due to AEs or lack of efficacy), and AEs (dizziness, somnolence, paresthesia, nausea, and asthenia).Results After MAIC weighting, effective sample size of rimegepant patients was 383.2 (25.3% of the original sample), and their aggregate baseline characteristics matched the zolmitriptan population. Rimegepant was associated with significantly lower risk of overall discontinuation than zolmitriptan (31.1% vs. 36.7%, OR: 0.8 [95%CI: 0.7, 0.9] ). Patients were less likely to discontinue rimegepant than zolmitriptan due to AEs (OR = 0.3 [0.2, 0.5]) and lack of efficacy (OR = 0.3 [0.2, 0.4]). Compared to zolmitriptan, rimegepant patients had reduced risk of experiencing all prespecified AEs.Conclusion Patients were less likely to discontinue rimegepant than zolmitriptan, due to AEs or lack of efficacy, and less likely to experience AEs of dizziness, somnolence, paresthesia, nausea, or asthenia over 12-months of use.grant.oneil@pfizer.com